Please set your pop-up blockers to allow pop-ups on www.peerviewpress.com. We use pop-ups to display content. Click Help for more information.

FEATURED PRESENTATION

Journal Club: Targeting Adenocarcinoma in NSCLC With Anti-Angiogenic Therapy

Interviewees
Alan Sandler, MD
Martin Reck, MD, PhD

Based on a review of "Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer" (Journal of Thoracic Oncology. 2010;5:1416-1423).

2010-10-18
Audio - Journal Club: Targeting Adenocarcinoma in NSCLC With Anti-Angiogenic Therapy
Alan Sandler, MD
Oregon Health & Science University
Portland, Oregon, USA
Audio - New Survival Data in Adenocarcinoma: Anti-Angiogenesis Therapy in the E4599 Study
Alan Sandler, MD
Oregon Health & Science University
Portland, Oregon, USA Download this Presentation's Materials
Slides
Printable Transcript
MP3
Audio - What the E4599 Study Means for Your Patients With Adenocarcinoma of the Lung
Martin Reck, MD, PhD
Hospital Grosshansdorf
Grosshansdorf, Germany Download this Presentation's Materials
Slides
Printable Transcript
MP3
2009-01-01 Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
2010-01-01 Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer.
2009-06-01 Recent developments of targeted therapies in the treatment of non-small cell lung cancer.
2010-03-01 The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
2010-07-01 Targeted therapies for non-small cell lung cancer: an evolving landscape.
2004-06-15 Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.